MCRC: Intensive triplet chemotherapy phase III studies: activity and efficacy
{"Image DocumentName": "MCRC: Intensive triplet chemotherapy phase III studies: activity and efficacy", "Image ImageDescription": "ORR. (%) PFS. (months) OS. Triplet CT Doublet+Bev Doublet+Cet Abbreviation: CT, chemotherapy; Bev, Bevacizumab; Cet, Cetuximab; ORR, objective response rate; PFS, progression-free survival; OS, overall survival. Bruera and Ricevuto, December \u201910.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}